SAN

77.51

+0.81%↑

ARGX

704.2

+0.46%↑

SHL.DE

35.06

+1.39%↑

FRE

38.4

-1.13%↓

PHIA

23.76

+1.45%↑

SAN

77.51

+0.81%↑

ARGX

704.2

+0.46%↑

SHL.DE

35.06

+1.39%↑

FRE

38.4

-1.13%↓

PHIA

23.76

+1.45%↑

SAN

77.51

+0.81%↑

ARGX

704.2

+0.46%↑

SHL.DE

35.06

+1.39%↑

FRE

38.4

-1.13%↓

PHIA

23.76

+1.45%↑

SAN

77.51

+0.81%↑

ARGX

704.2

+0.46%↑

SHL.DE

35.06

+1.39%↑

FRE

38.4

-1.13%↓

PHIA

23.76

+1.45%↑

SAN

77.51

+0.81%↑

ARGX

704.2

+0.46%↑

SHL.DE

35.06

+1.39%↑

FRE

38.4

-1.13%↓

PHIA

23.76

+1.45%↑

Kodu・Aktsiate loetelu・Genfit

Genfit

Suletud

SektorTervishoid

8.45

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.45

Max

8.68

Põhinäitajad
By Trading Economics
Sissetulek	-66M -76M
Müük	-3.6M 32M
Aktsiakasum	-1.525
Kasumimarginaal	-237.939
Töötajad	188
EBITDA	-8M -7M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+76.06% upside

Turustatistika
By TradingEconomics
Turukapital	53M 426M
Eelmine avamishind	8.45
Eelmine sulgemishind	8.45

Uudiste sentiment

By Acuity

36%

64%

105 / 345 Pingereas Healthcare

Genfit Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. mai 2026, 08:24 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25. mai 2026, 21:22 UTC

Tulu

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25. mai 2026, 20:50 UTC

Market Talk

Tulu

Basic Materials Roundup: Market Talk

25. mai 2026, 16:20 UTC

Market Talk

Tulu

Basic Materials Roundup: Market Talk

25. mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25. mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25. mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25. mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25. mai 2026, 12:56 UTC

Market Talk

Tulu

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25. mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25. mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25. mai 2026, 12:10 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Delivery Hero's Assets Look Strategic -- Market Talk

25. mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25. mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25. mai 2026, 10:05 UTC

Tulu

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25. mai 2026, 10:04 UTC

Tulu

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25. mai 2026, 10:03 UTC

Tulu

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25. mai 2026, 10:02 UTC

Tulu

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25. mai 2026, 10:01 UTC

Tulu

Tenaga Nasional 1Q Net Up 3.7% on Year

25. mai 2026, 10:00 UTC

Tulu

Tenaga Nasional 1Q Rev Up 6.6% on Year

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q EPS MYR0.1883

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q Rev MYR17.1B

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q Net MYR1.1B

25. mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25. mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25. mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25. mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Genfit Prognoos

Hinnasiht

By TipRanks

76.06% tõus

12 kuu keskmine prognoos

Keskmine 15 EUR 76.06%

Kõrge 15 EUR

Madal 15 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Genfit 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Genfit aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

105 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.